Antiarrhythmic activity of esmolol (ASL-8052)--a novel ultra-short acting beta-adrenoreceptor blocking agent.
Int J Clin Pharmacol Ther Toxicol
; 22(2): 112-7, 1984 Feb.
Article
en En
| MEDLINE
| ID: mdl-6142005
ABSTRACT
In a single-blind, placebo-controlled study, esmolol was administered intravenously to 12 patients with chronic atrial fibrillation. Esmolol produced a significant dose-dependent decrease in the ventricular rate without conversion to normal sinus rhythm in any of the patients. For most patients, a correlation was observed between the blood levels of esmolol and reductions in heart rate. There were no significant adverse effects. We conclude that esmolol is an effective and safe agent for the control of heart rate in patients with supraventricular tachycardia.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Propanolaminas
/
Fibrilación Atrial
/
Antagonistas Adrenérgicos beta
/
Antiarrítmicos
Tipo de estudio:
Clinical_trials
Límite:
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Int J Clin Pharmacol Ther Toxicol
Año:
1984
Tipo del documento:
Article